Περίληψη:
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events. © 2018 The Author(s).
Συγγραφείς:
Ludwig, H.
Delforge, M.
Facon, T.
Einsele, H.
Gay, F.
Moreau, P.
Avet-Loiseau, H.
Boccadoro, M.
Hajek, R.
Mohty, M.
Cavo, M.
Dimopoulos, M.A.
San-Miguel, J.F.
Terpos, E.
Zweegman, S.
Garderet, L.
Mateos, M.-V.
Cook, G.
Leleu, X.
Goldschmidt, H.
Jackson, G.
Kaiser, M.
Weisel, K.
Van De Donk, N.W.C.J.
Waage, A.
Beksac, M.
Mellqvist, U.H.
Engelhardt, M.
Caers, J.
Driessen, C.
Bladé, J.
Sonneveld, P.
Λέξεις-κλειδιά:
bortezomib; carfilzomib; daratumumab; elotuzumab; ixazomib; lenalidomide; panobinostat; pomalidomide; proteasome; thalidomide; antineoplastic agent, adverse event; allergic reaction; amenorrhea; anemia; bacterial infection; bleeding; bradycardia; cardiotoxicity; cataract; clinical practice; constipation; Cytomegalovirus; deep vein thrombosis; diarrhea; disease severity; dizziness; dyspnea; edema; enzyme inhibition; faintness; hepatitis B; hepatitis C; herpes zoster; human; hypertension; hypotension; immunomodulation; incidence; infection; infection prevention; infusion related reaction; liver toxicity; lung disease; multiple myeloma; muscle cramp; mycosis; nausea; nephrotoxicity; neutropenia; patient care; patient monitoring; peripheral neuropathy; posterior reversible encephalopathy syndrome; practice guideline; priority journal; progressive multifocal leukoencephalopathy; Review; risk factor; second cancer; seizure; skin manifestation; somnolence; teratogenicity; thrombocytopenia; thromboembolism; thyroid disease; toxicity; treatment outcome; tumor lysis syndrome; vaccination; vascular toxicity; virus infection; vomiting; adverse drug reaction; complication; consensus development; disease management; molecularly targeted therapy; multiple myeloma; risk assessment, Antineoplastic Agents; Disease Management; Drug-Related Side Effects and Adverse Reactions; Humans; Incidence; Molecular Targeted Therapy; Multiple Myeloma; Practice Guidelines as Topic; Risk Assessment
